| Literature DB >> 35651673 |
Mohamed Farah Yusuf Mohamud1, Mahad Sadik Mukhtar1.
Abstract
Background: Septic pulmonary embolism (SPE) is an unusual condition characterized by the implantation of infected thrombi into the pulmonary vasculature from a variety of infectious sources. This study aimed to illustrate the clinicoradiological features, microbiological spectrum, and clinical course of patients with SPE, as well as to promote the early identification, diagnosis, and prognosis of this unusual disease.Entities:
Keywords: chest CT scan; emergency; hemodialysis; intensive care unit; septic pulmonary embolism
Year: 2022 PMID: 35651673 PMCID: PMC9148921 DOI: 10.2147/IJGM.S364522
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Baseline Characteristics, Laboratory Findings and Outcomes of 19 Patients Diagnosed and Treated with Septic Pulmonary Emboli Between Years 2017 and 2020
| Variables | Frequency | Percentage | |
|---|---|---|---|
| 49 (15–78) | |||
| Sex | Male | 12 | 63.2% |
| Female | 7 | 36.8% | |
| Site of admission | Normal service | 11 | 57.9% |
| ICU | 8 | 42.1% | |
| Site of culture microorganism | Blood culture | 11 | 57.9% |
| Urine culture | 3 | 15.8% | |
| Soft tissue culture | 3 | 15.8% | |
| Sputum culture | 2 | 10.5% | |
| Source of infection | Venous catheter associated blood stream infection | 11 | 57.9% |
| Soft tissue and bone | 4 | 21% | |
| Pretonsilarabcess | 2 | 10.5% | |
| Urine | 1 | 5.3% | |
| Infective endocarditis | 1 | 5.3% | |
| Outcome | Recovery | 14 | 73.7% |
| Death | 5 | 26.3% | |
| Comorbids | |||
| Chronic renal failure | 13 | 68.4% | |
| Diabetes | 7 | 36.8% | |
| Hypertension | 5 | 26.3% | |
| Heart failure | 3 | 15.8% | |
| Chronic liver disease | 2 | 10.5% | |
| Cerebrovascular disease | 2 | 10.5% | |
| Venous thromboembolism | 1 | 5.3% | |
| Malignant | 1 | 5.3% | |
| Predisposing factors | |||
| Venous catheter | 12 | 63.2% | |
| Immunocompromised | 10 | 53.6% | |
| Nosocomial infection | 12 | 63.2% | |
| Trauma | 4 | 21% | |
| IV drug users | 1 | 5.3% | |
| Others | 3 | 15.8% | |
| Clinical features | |||
| Fever | 15 | 79% | |
| Shortness of breath | 14 | 73.7% | |
| Cough | 10 | 53.6% | |
| Hemoptysis | 5 | 26.3% | |
| Chest pain | 9 | 47.4% | |
| Altered level of conscious | 7 | 36.8% | |
| Hypotension | 5 | 26.3% | |
| Others | 3 | 15.8% | |
| Vital signs | |||
| SBP- mean (range) mmHg | 121 | 66–207 | |
| DBP- mean (range) mmHg | 70.9 | 33–114 | |
| SPo2- mean (range) % | 88.9 | 65–99 | |
| RR- mean (range) Breath per minute | 19.4 | 14–28 | |
| HR- mean (range) beats per minute | 98.9 | 69–139 | |
| Laboratory investigation | |||
| WBC | 14.3 | 2.7–23.7 | |
| Neutrophils | 71.7 | 10.5–95.5 | |
| HB | 98.9 | 69–139 | |
| Platelets | 98.9 | 69–139 | |
| ESR | 97.3 | 45–217 | |
| CRP | 125.6 | 24.2–316.9 | |
| AST | 67.6 | 10–275 | |
| ALT | 38.6 | 3–272 | |
| UREA | 141.8 | 31–358 | |
| Creatinine | 5.3 | 0.61–15.68 | |
| INR | 1.5 | 0.8–3 | |
Microbiologic Features, Chest Computed Tomographic Findings, and Management of 19 Patients Diagnosed with Septic Pulmonary Emboli Between Years 2017 and 2020
| Variables | Frequency | Percentage | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 52.6% | |||||||||||||||
| 3 | 15.8 | |||||||||||||||
| 2 | 10.5 | |||||||||||||||
| 1 | 5.3% | |||||||||||||||
| 1 | 5.3% | |||||||||||||||
| 1 | 5.3% | |||||||||||||||
| 1 | 5.3% | |||||||||||||||
| 100 and | 100 and | 90% | 70% | 90% | 40% | 0% | 0% | 10% | 0% | 0% | 0% | |||||
| 100 and | 100 and | 50% | 50% | 100 and | 50% | 0 and | 0 and | 0 and | 0 and | 0 and | 0 and | |||||
| 100 and | 100% | 50% | 50% | 100% | 50% | 0% | 0% | 50% | 50% | 0% | 0% | |||||
| 100 and | 100 and | 100 and | 100 and | 100 and | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||
| 100 and | 100 and | 100 and | 100% | 0% | 100% | 0% | 100% | 0% | 100% | 0% | 0% | |||||
| 100% | 100% | 100% | 0% | 100% | 0% | 0% | 0% | 100% | 100% | 0% | 0% | |||||
| 100% | 100% | 100% | 0% | 100% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||
| Location of the lesion | Central | 9 | 47.4% | |||||||||||||
| Peripheral | 5 | 26.3% | ||||||||||||||
| Diffuse | 5 | 26.3% | ||||||||||||||
| Type of lesion | Bilateral opacities | 19 | 100% | |||||||||||||
| Nodular | 14 | 73.9% | ||||||||||||||
| Cavitation | 11 | 57.9% | ||||||||||||||
| Consolidation | 9 | 47.4% | ||||||||||||||
| Non nodular | 5 | 26.3% | ||||||||||||||
| Pleural effusion | 5 | 26.3% | ||||||||||||||
| Feeding vessel sign | 3 | 15.8% | ||||||||||||||
| Lymphoadenopathy | 1 | 5.3% | ||||||||||||||
| Echocardiography | Yes | 15 | 79% | |||||||||||||
| No | 4 | 21% | ||||||||||||||
| Antibiotics | 19 | 100% | ||||||||||||||
| Systemic anticoagulant | 13 | 68.4% | ||||||||||||||
| Extrapulmonary fasicotomy +or abscess drainage or debridement | 5 | 26.3% | ||||||||||||||
Abbreviations: STX, trimethoprim/sulfamethoxazole; PG, penicillin G; PT, piperacillin/tazobactam; GM, gentomycine; CTX, ceftriaxone; LF, levofloxacin; CL, clindamycin; VM, vancomycin; MP, meropenem; IP, imipenem; TC, tetracycline; AK, amikacin.
Figure 1(A and B). Panel (A): An axial enhanced chest CT scan demonstrating Multiple predominantly solid pulmonary nodules randomly distributed throughout both lungs, some of which with central cavitations in the right side. Panel (B): An axial enhanced chest CT scan showing with multiple small peripheral cavitating pulmonary nodules with bilateral pleural effusion.
Figure 2(A and B). Panel (A): A transthoracic echocardiography study of a 33 years old male revealed with a large, echogenic mobile focus attached to the tricuspid valve.Panel (B) : A transthoracic echocardiography finding demonstrated with severe tricuspid regurgitation.
Baseline Characteristics, Univariate Analysis and Logistic Regression Analysis of Outcome Factors for 19 Patients with SPE Between Years 2017 and 2020
| Variables | Frequency (%) | Outcome of the Patients | Logistic Regression Analysis | |||
|---|---|---|---|---|---|---|
| Vital Signs | Mean Range | Recovered | Died | P value | CI Interval | |
| Upper | Lower | |||||
| Systolic BP | 123.6mmHg | 14 | 5 | 0.257 | 0.942 | 1.211 |
| Diastolic BP | 70.90mmHg | 14 | 5 | 0.090 | 0.560 | 1.103 |
| Heart Rate | 98.90bpm | 14 | 5 | 0.080 | 0.814 | 1.404 |
| SPO2 | 88.90% | 14 | 5 | 0.035 | 0.706 | 2.130 |
| Respiratory Rate | 19.47bpm | 14 | 5 | 0.120 | 0.934 | 1.469 |
| Fever | 15 (79%) | 14 | 5 | 0.160 | ||
| Dyspnea | 14 (73.7%) | 14 | 5 | 0.160 | ||
| Cough | 10 (52.6%) | 14 | 5 | 0.814 | ||
| Chest pain | 9 (47.4%) | 14 | 5 | 0.648 | ||
| Altered mental status | 8 (42.1%) | 14 | 5 | 0.026 | ||
| Hemoptysis | 5 (26.3%) | 14 | 5 | 0.599 | ||
| Hypotension and shock | 4 (21%) | 14 | 5 | 0.261 | ||
| Other symptoms | 3 (15.8%) | 14 | 5 | 0.814s | ||
| Venous Catheter Insertion | 12 (63.2%) | 14 | 5 | 0.363 | ||
| Nosocomial infection | 12 (63.2%) | 14 | 5 | 0.865 | ||
| Immunosuppressed state | 10 (52.6%) | 14 | 5 | 0.701 | ||
| Trauma | 4 (21.05%) | 14 | 5 | 0.226 | ||
| Other factors | 3 (15.8%) | 14 | 5 | 0.764 | ||
| IV Drug use | 1 (5.3%) | 14 | 5 | 0.086 | ||
| Chronic renal failure | 14 (73.7%) | 14 | 5 | 0.709 | ||
| Diabetes Mellitus | 7 (36.8%) | 14 | 5 | 0.363 | ||
| Hypertension | 5 (26.3%) | 14 | 5 | 0.418 | ||
| Heart failure | 3 (15.8%) | 14 | 5 | 0.764 | ||
| Liver failure | 2 (10.5%) | 14 | 5 | 0.372 | ||
| Cerebrovascular disease | 2 (10.5%) | 14 | 5 | 0.372 | ||
| Venous thromboembolism | 1 (5.3%) | 14 | 5 | 0.086 | ||
| Malignancy | 1 (5.3%) | 14 | 5 | 0.539 | ||
| WBC | 14.3505 | 14 | 5 | 0.589 | 0.701 | 1.475 |
| Neutrophils | 71.6705 | 14 | 5 | 0.155 | 0.928 | 1.312 |
| ESR | 97.2632 | 14 | 5 | 0.885 | 0.957 | 1.157 |
| CRP | 125.5637 | 14 | 5 | 0.706 | 0.954 | 1.028 |
| AST | 67.2632 | 14 | 5 | 0.196 | 0.978 | 1.050 |
| ALT | 38.5789 | 14 | 5 | 0.866 | 0.959 | 1.025 |
| INR | 8.9953 | 14 | 5 | 0.552 | 0.792 | 1.325 |
| Creatinine | 5.3474 | 14 | 5 | 0.144 | 0.446 | 1.737 |
| UREA | 141.7895 | 14 | 5 | 0.081 | 0.970 | 1.047ss |
| Non nodular | 5 (26.3%) | 14 | 5 | 0.120 | ||
| Cavitation | 11 (57.9%) | 14 | 5 | 0.912 | ||
| Consolidations | 9 (47.4%) | 14 | 5 | 0.701 | ||
| Feeding vessel ring | 3 (15.8%) | 14 | 5 | 0.084 | ||
| Lymphadenopathy | 1 (5.3%) | 14 | 5 | 0.539 | ||
| Pleural effusion | 5 (26.3%) | 14 | 5 | 0.120 | ||
| Central lesion | 5 (26.3%) | 14 | 5 | 0.418 | ||
| Peripheral lesion | 9 (47.4%) | 14 | 5 | 0.701 | ||
| Diffuse lesion | 4 (21.05%) | 14 | 5 | 0.380 | ||